(Reuters) – The U.S. Food & Drug Administration is expected to authorize a booster shot of Pfizer/BioNTech’s COVID-19 vaccine for children aged 5 to 11 as soon as Tuesday, the New York Times reported on Monday, citing people familiar with the matter (Reporting by Mrinalika Roy in Bengaluru; Editing by Anil D’Silva)